Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 36
Filtrar
Más filtros

Medicinas Complementárias
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
J Anal Toxicol ; 43(4): e23-e27, 2019 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-30566569

RESUMEN

BACKGROUND: Ayahausca is an ethnobotanical drink of South America and the compound dimethyltryptamine (DMT) is primarily responsible for the hallucinogenic effects. DMT has a short half-life and its detection in urinary drug screens is challenging. We investigate a simple alternate approach to detect ayahuasca consumption by relying on other constituents of the drink, the ß-carboline harmala alkaloids. METHODS: Three commercially sourced harmala alkaloids were characterized and added to a non-targeted high-resolution mass spectrometry urine drug screening method. All analyses were performed on a Waters Xevo G2-XS LC-QTof, in positive electrospray ionization mode. The mass detector was operated in MSE mode and data processed with UNIFI™ software. A urine specimen from a patient suspected to have consumed ayahuasca was analyzed by a non-targeted drug screen. RESULTS: The harmala alkaloids: harmine, harmaline and tetrohydroharmaline (THH) were characterized and their detection data added to the toxicology screening library. Harmaline and THH were detected in the patient's urine specimen. CONCLUSION: The inclusion of the harmala alkaloids into the drug screen method library may enable the detection of ayahuasca use in patients that undergo non-targeted drug screen.


Asunto(s)
Banisteriopsis/química , Alcaloides de Harmala/orina , Extractos Vegetales/orina , Detección de Abuso de Sustancias/métodos , Trastornos Relacionados con Sustancias/orina , Adulto , Antimaníacos/uso terapéutico , Antipsicóticos/uso terapéutico , Cromatografía Liquida , Alucinógenos/toxicidad , Alucinógenos/orina , Humanos , Masculino , Espectrometría de Masas , N,N-Dimetiltriptamina/toxicidad , N,N-Dimetiltriptamina/orina , Olanzapina/uso terapéutico , Psicosis Inducidas por Sustancias/tratamiento farmacológico , Resultado del Tratamiento , Ácido Valproico/uso terapéutico
2.
Reprod Toxicol ; 77: 143-153, 2018 04.
Artículo en Inglés | MEDLINE | ID: mdl-29522798

RESUMEN

Rats were treated orally with ayahuasca (AYA) on gestation days (GD) 6-20 at doses corresponding to one-(1X) to eight-fold (8X) the average dose taken by a human adult in a religious ritual, and the pregnancy outcome evaluated on GD21. Rats treated with 4X and 8X doses died during the treatment period (44 and 52%), and those that survived showed kidney injury. Rats surviving the 8X dose showed neuronal loss in hippocampal regions and in the raphe nuclei, and those from the 2X dose neuronal loss in CA1. Delayed intrauterine growth, induced embryo deaths and increased occurrence of foetal anomalies were observed at the 8X dose. At non-lethal doses, AYA enhanced embryolethality and the incidence of foetal soft-tissue and skeleton anomalies. This study suggested that AYA is developmentally toxic and that its daily use by pregnant women may pose risks for the conceptus.


Asunto(s)
Banisteriopsis , Bebidas/toxicidad , Alucinógenos/toxicidad , Preparaciones de Plantas/toxicidad , Teratógenos/toxicidad , Anomalías Inducidas por Medicamentos , Anomalías Múltiples/inducido químicamente , Animales , Encéfalo/anomalías , Encéfalo/efectos de los fármacos , Encéfalo/patología , Embrión de Mamíferos/efectos de los fármacos , Femenino , Retardo del Crecimiento Fetal , Riñón/anomalías , Riñón/efectos de los fármacos , Hígado/anomalías , Hígado/efectos de los fármacos , Masculino , Intercambio Materno-Fetal , Neuronas/efectos de los fármacos , Embarazo , Ratas Wistar , Esqueleto/anomalías , Esqueleto/efectos de los fármacos , Testículo/anomalías , Testículo/efectos de los fármacos , Uréter/anomalías , Uréter/efectos de los fármacos , Útero/anomalías , Útero/efectos de los fármacos
4.
Neurotox Res ; 30(4): 606-619, 2016 11.
Artículo en Inglés | MEDLINE | ID: mdl-27461536

RESUMEN

5-Methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT, 'foxy') is one of the most popular tryptamine hallucinogens in the illicit drug market. It produces serious adverse effects, but its pharmacological profile is not well recognized. In vitro data have shown that 5-MeO-DIPT acts as a potent serotonin transporter (SERT) inhibitor and displays high affinity at serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors. In this study, using microdialysis in freely moving rats, we examined the effect of 5-MeO-DIPT on dopamine (DA), serotonin (5-HT), and glutamate release in the rat striatum, nucleus accumbens, and frontal cortex. In search of a possible neurotoxic effect of 5-MeO-DIPT, we measured DA and 5-HT tissue content in the above rat brain regions and also determined the oxidative DNA damage with the comet assay. Moreover, we tested drug-elicited head-twitch response and a forepaw treading induced by 8-OH-DPAT. 5-MeO-DIPT at doses of 5, 10, and 20 mg/kg increased extracellular DA, 5-HT, and glutamate level but the differences in the potency were found between brain regions. 5-MeO-DIPT increased 5-HT and decreased 5-HIAA tissue content which seems to result from SERT inhibition. On the other hand, a decrease in DA, DOPAC, and HVA tissue contents suggests possible adaptive changes in DA turnover or damage of DA terminals by 5-MeO-DIPT. DNA single and double-strand breaks persisted up to 60 days after the treatment, indicating marked neurotoxicity of 5-MeO-DIPT. The induction of head-twitch response and potentiation of forepaw treading induced by 8-OH-DPAT indicate that hallucinogenic activity seems to be mediated through the stimulation of 5-HT2A and 5-HT1A receptors by 5-MeO-DIPT.


Asunto(s)
5-Metoxitriptamina/análogos & derivados , Cuerpo Estriado/efectos de los fármacos , Lóbulo Frontal/efectos de los fármacos , Alucinógenos/toxicidad , Núcleo Accumbens/efectos de los fármacos , 5-Metoxitriptamina/toxicidad , 8-Hidroxi-2-(di-n-propilamino)tetralin/farmacología , Anfetaminas/farmacología , Análisis de Varianza , Animales , Cuerpo Estriado/metabolismo , Daño del ADN/efectos de los fármacos , Dopamina/metabolismo , Lóbulo Frontal/metabolismo , Ácido Glutámico/metabolismo , Drogas Ilícitas/toxicidad , Masculino , Microdiálisis , Actividad Motora/efectos de los fármacos , Actividad Motora/fisiología , N-Metil-3,4-metilenodioxianfetamina/toxicidad , Núcleo Accumbens/metabolismo , Estrés Oxidativo/efectos de los fármacos , Ratas Wistar , Serotonina/metabolismo
6.
Eur Neuropsychopharmacol ; 25(12): 2404-15, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26499171

RESUMEN

Over 180 million people consume cannabis globally. Cannabis use peaks during adolescence with a trend for continued consumption by adults. Notably, several studies have shown that long-term and heavy cannabis use during adolescence can impair brain maturation and predispose to neurodevelopmental disorders, although the neurobiological mechanisms underlying this association remain largely unknown. In this study, we evaluated whether, in female rats, chronic administration of increasing doses of the psychotropic plant-derived cannabis constituent, delta-9-tetrahydrocannabinol (THC), during adolescence (PND 35-45) could affect microglia function in the long-term. Furthermore, we explored a possible contribution of microglia to the development of THC-induced alterations in mood and cognition in adult female rats. Present data indicate that adolescent THC administration induces a persistent neuroinflammatory state specifically localized within the adult prefrontal cortex (PFC), characterized by increased expression of the pro-inflammatory markers, TNF-α, iNOS and COX-2, and reduction of the anti-inflammatory cytokine, IL-10. This neuroinflammatory phenotype is associated with down-regulation of CB1 receptor on neuronal cells and up-regulation of CB2 on microglia cells, conversely. Interestingly, blocking microglia activation with ibudilast during THC treatment significantly attenuates short-term memory impairments in adulthood, simultaneously preventing the increases in TNF-α, iNOS, COX-2 levels as well as the up-regulation of CB2 receptors on microglia cells. In contrast, THC-induced depressive-like behaviors were unaffected by ibudilast treatment. Our findings demonstrate that adolescent THC administration is associated with persistent neuroinflammation within the PFC and provide evidence for a causal association between microglial activation and the development long-term cognitive deficits induced by adolescent THC treatment.


Asunto(s)
Trastornos del Conocimiento/etiología , Dronabinol/toxicidad , Encefalitis , Alucinógenos/toxicidad , Corteza Prefrontal/patología , Factores de Edad , Animales , Animales Recién Nacidos , Ciclooxigenasa 2/metabolismo , Citocinas/metabolismo , Modelos Animales de Enfermedad , Encefalitis/inducido químicamente , Encefalitis/complicaciones , Encefalitis/patología , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Pérdida de Tono Postural/efectos de los fármacos , Relaciones Interpersonales , Óxido Nítrico Sintasa de Tipo II/metabolismo , Inhibidores de Fosfodiesterasa/farmacología , Piridinas/farmacología , Ratas , Ratas Sprague-Dawley , Reconocimiento en Psicología/efectos de los fármacos , Natación/psicología
7.
J Proteome Res ; 14(8): 3174-87, 2015 Aug 07.
Artículo en Inglés | MEDLINE | ID: mdl-26043028

RESUMEN

Schizophrenia is a neuropsychiatric disorder affecting 1% of the world's population. Due to both a broad range of symptoms and disease heterogeneity, current therapeutic approaches to treat schizophrenia fail to address all symptomatic manifestations of the disease. Therefore, disease models that reproduce core pathological features of schizophrenia are needed for the elucidation of pathological disease mechanisms. Here, we employ a comprehensive global label-free liquid chromatography-mass spectrometry proteomic (LC-MS(E)) and metabonomic (LC-MS) profiling analysis combined with the targeted proteomics (selected reaction monitoring and multiplex immunoassay) of serum and brain tissues to investigate a chronic phencyclidine (PCP) rat model in which glutamatergic hypofunction is induced through noncompetitive NMDAR-receptor antagonism. Using a multiplex immunoassay, we identified alterations in the levels of several cytokines (IL-5, IL-2, and IL-1ß) and fibroblast growth factor-2. Extensive proteomic and metabonomic brain tissue profiling revealed a more prominent effect of chronic PCP treatment on both the hippocampal proteome and metabonome compared to the effect on the frontal cortex. Bioinformatic pathway analysis confirmed prominent abnormalities in NMDA-receptor-associated pathways in both brain regions, as well as alterations in other neurotransmitter systems such as kainate, AMPA, and GABAergic signaling in the hippocampus and in proteins associated with neurodegeneration. We further identified abundance changes in the level of the superoxide dismutase enzyme (SODC) in both the frontal cortex and hippocampus, which indicates alterations in oxidative stress and substantiates the apoptotic pathway alterations. The present study could lead to an increased understanding of how perturbed glutamate receptor signaling affects other relevant biological pathways in schizophrenia and, therefore, support drug discovery efforts for the improved treatment of patients suffering from this debilitating psychiatric disorder.


Asunto(s)
Apoptosis/efectos de los fármacos , Metabolómica/métodos , Estrés Oxidativo/efectos de los fármacos , Fenciclidina/toxicidad , Proteómica/métodos , Transmisión Sináptica/efectos de los fármacos , Animales , Cromatografía Liquida , Citocinas/sangre , Citocinas/metabolismo , Modelos Animales de Enfermedad , Lóbulo Frontal/efectos de los fármacos , Lóbulo Frontal/metabolismo , Alucinógenos/toxicidad , Hipocampo/efectos de los fármacos , Hipocampo/metabolismo , Humanos , Masculino , Espectrometría de Masas , Metaboloma/efectos de los fármacos , Proteoma/metabolismo , Ratas Sprague-Dawley , Esquizofrenia/sangre , Esquizofrenia/inducido químicamente , Esquizofrenia/metabolismo , Transducción de Señal/efectos de los fármacos , Superóxido Dismutasa/metabolismo
8.
Int J Med Mushrooms ; 17(11): 1019-29, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26853956

RESUMEN

This paper is a review of the new studies or new explanations of the hallucinogenic mushrooms, regarding their diversity, history, traditions, and problems in their recreational use, new taxonomic studies, and their modern applications in medicine, all of them since the 1970s to the present.


Asunto(s)
Agaricales/química , Alucinógenos/análisis , Psiquiatría/historia , Agaricales/clasificación , Agaricales/crecimiento & desarrollo , Animales , Alucinógenos/historia , Alucinógenos/toxicidad , Historia del Siglo XVI , Historia del Siglo XVII , Historia del Siglo XVIII , Historia del Siglo XIX , Historia del Siglo XX , Historia del Siglo XXI , Humanos
9.
Eur Neuropsychopharmacol ; 24(8): 1415-23, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24846537

RESUMEN

Cannabis produces cognitive dysfunctions that resemble those of schizophrenia; yet the neurobiological substrate of this similarity remains unclear. Schizophrenia patients show deficits in prepulse inhibition (PPI) of the acoustic startle reflex (ASR), an operational measure of the information-processing abnormalities that may underlie the cognitive and positive symptoms of the disease. However, the effect of cannabis on PPI remains poorly understood, as data are often contradictory. Here, we investigated the effect of acute and repeated treatment with ∆(9)-tetrahydrocannabinol (THC), the main psychoactive constituent of cannabis, on PPI in rats, and the role of dopamine D2/3-receptor blockade in this effect. PPI and ASR were sequentially measured after the first and the last dose of a 21-days treatment with THC (1 mg/kg/day) or vehicle and at 1-week following discontinuation of treatment. The effect of haloperidol (0.1 mg/kg) on THC-induced PPI alteration was also evaluated. Chronic, but not acute, THC treatment produced significant reductions in PPI that were normalized back to control values within one-week of THC discontinuation. The THC-induced gating deficits were observed in the absence of ASR change and were reversed by the D2/3-receptor antagonist haloperidol. Chronic THC exposure induced PPI disruptions that emerged only following repeated administrations, suggesting that time-dependent neuroadaptations within the DA mesolimbic system are involved in the disruptive effects of THC on sensorimotor gating. These gating deficits were transient and appeared to be dependent on an overactivity of D2/3-receptor-mediated dopamine signaling, highlighting a potential role for D2/3-receptors in the propsychotic action of THC.


Asunto(s)
Antagonistas de Dopamina/uso terapéutico , Dronabinol/toxicidad , Trastornos Neurológicos de la Marcha/inducido químicamente , Trastornos Neurológicos de la Marcha/tratamiento farmacológico , Alucinógenos/toxicidad , Haloperidol/uso terapéutico , Inhibición Prepulso/efectos de los fármacos , Estimulación Acústica , Análisis de Varianza , Animales , Modelos Animales de Enfermedad , Masculino , Psicoacústica , Ratas , Ratas Sprague-Dawley , Factores de Tiempo
10.
Neurosci Biobehav Rev ; 37(4): 658-67, 2013 May.
Artículo en Inglés | MEDLINE | ID: mdl-23458778

RESUMEN

The role of cannabis in the etiology of schizophrenia has been documented as possibly the strongest environmental risk factor. However, the pathomechanism whereby cannabis use increases this risk has not yet been identified. We argue that this pathomechanism may involve direct effects of exogenous cannabinoids on T-type calcium channels in the thalamus. These channels are crucial for amplification of corticothalamic inputs, as well as for the ability of the thalamus to generate neuronal burst firing. Cortically induced thalamic burst firing has been found to be important in trans-thalamic cortico-cortical interactions. Therefore, any potential interference with the burst firing mode in the thalamus could lead to an impairment in these interactions, which in turn causes a relative disconnection between cortical areas. This in turn could result in reduced ability to recognize re-afferent sensory inputs and psychosis. We also argue that the effects of Δ(9)THC are more detrimental compared with the effects of cannabidiol, as the former may increase the excitability of thalamic neurons by its direct effect on T-type calcium channels.


Asunto(s)
Cannabis , Psicosis Inducidas por Sustancias/fisiopatología , Psicosis Inducidas por Sustancias/psicología , Trastornos Psicóticos/fisiopatología , Trastornos Psicóticos/psicología , Tálamo/fisiopatología , Animales , Canales de Calcio Tipo T/efectos de los fármacos , Canales de Calcio Tipo T/fisiología , Cannabinoides/farmacología , Corteza Cerebral/fisiopatología , Dronabinol/toxicidad , Electroencefalografía , Alucinógenos/toxicidad , Humanos , Vías Nerviosas/efectos de los fármacos , Esquizofrenia/fisiopatología , Psicología del Esquizofrénico
11.
Psychopharmacology (Berl) ; 225(3): 531-42, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22903392

RESUMEN

RATIONALE: Chronic cannabis use can induce psychotic states that resemble schizophrenia. Yet, schizophrenic patients often smoke cannabis as a form of self-medication to counter the aversive symptoms of schizophrenia. We recently demonstrated an ameliorating effect of cannabinoid self-administration (SA) on negative and cognitive schizophrenia-like symptoms induced experimentally by the non-competitive N-methyl-D-aspartate receptor antagonist phencyclidine (PCP). Whether cannabinoid SA alleviates or exacerbates schizophrenia-like positive symptoms is still unclear. OBJECTIVES: This follow-up study aimed to evaluate the effect of self-administered cannabinoid on PCP-induced schizotypic positive symptoms in adult rats. METHODS: Male rats were trained to self-administer either the cannabinoid CB1 receptor agonist WIN 55,212-2 (WIN; 12.5 µg/kg/infusion) or its vehicle (Veh) intravenously. The effects of acute and chronic intermittent intraperitoneal administration of PCP (2.5 mg/kg) on motor parameters were then tested in Veh-SA and WIN-SA. RESULTS: Cannabinoid SA significantly attenuated the psychotomimetic effects of PCP exposure observed in control rats. Following acute PCP administration, WIN-SA animals displayed more frequent rearing and lower anxiety-like profile than Veh-SA rats. WIN-SA rats also exhibited lower behavioural sensitisation to chronic PCP treatment as demonstrated by reduced hyperlocomotion in response to an acute PCP challenge. In addition, parallel experiments performed in experimenter-administered rats that received WIN at comparable SA doses confirmed the ameliorating effects of cannabinoid exposure on PCP-induced schizotypic behaviours, indicating that motivational effects were not responsible for the ameliorative effects of cannabinoids. CONCLUSIONS: Our results indicate that cannabis may exert protective effects on positive schizotypic symptoms in adult animals such as hypermotility and anxiety state.


Asunto(s)
Conducta Animal/efectos de los fármacos , Cannabinoides/uso terapéutico , Alucinógenos/toxicidad , Fenciclidina/toxicidad , Esquizofrenia/prevención & control , Psicología del Esquizofrénico , Animales , Ansiedad/inducido químicamente , Ansiedad/prevención & control , Benzoxazinas/administración & dosificación , Benzoxazinas/uso terapéutico , Agonistas de Receptores de Cannabinoides/administración & dosificación , Agonistas de Receptores de Cannabinoides/uso terapéutico , Cannabinoides/administración & dosificación , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Inyecciones Intravenosas , Masculino , Morfolinas/administración & dosificación , Morfolinas/uso terapéutico , Actividad Motora/efectos de los fármacos , Naftalenos/administración & dosificación , Naftalenos/uso terapéutico , Ratas , Ratas Endogámicas , Esquizofrenia/inducido químicamente , Autoadministración
12.
Neurosci Lett ; 531(2): 198-203, 2012 Dec 07.
Artículo en Inglés | MEDLINE | ID: mdl-23142720

RESUMEN

3,4-Methylenedioxymethamphetamine (MDMA) is an illegal drug that can induce life-threatening hyperthermia. No effective pharmacological treatment for MDMA-induced hyperthermia has yet been established. We investigated the effects of memantine, a non-competitive N-methyl-D-aspartate (NMDA)-type glutamate receptor antagonist and an α-7 nicotinic acetylcholine receptor (nAChR) antagonist, on MDMA-induced hyperthermia in rats. Treatment of animals with memantine (10 or 20 mg/kg) either before or after MDMA (10 mg/kg) administration significantly decreased the peak body temperature. Results from our microdialysis study indicated that pretreatment with memantine (20 mg/kg) before MDMA administration had no effect on the MDMA-induced increase in serotonin (5-HT) and dopamine (DA) levels in the anterior hypothalamus. MDMA-induced hyperthermia was significantly suppressed by pretreatment with the non-competitive NMDA receptor antagonist MK-801 (0.5 mg/kg) and the competitive NMDA antagonist CGS 19755 (5 mg/kg), but not by the selective α-7 nAChR antagonist methyllycaconitine (6 or 10 mg/kg). These results indicate that the inhibitory effect of memantine on MDMA-induced hyperthermia may be due to its activity as an NMDA receptor antagonist and not as a result of a direct effect on the 5-HT or DA systems. The present study suggests that moderate doses of memantine may be useful for the treatment of MDMA-induced hyperthermia in humans.


Asunto(s)
Dopaminérgicos/farmacología , Fiebre/tratamiento farmacológico , Alucinógenos/toxicidad , Memantina/farmacología , N-Metil-3,4-metilenodioxianfetamina/toxicidad , Animales , Química Encefálica/efectos de los fármacos , Cromatografía Líquida de Alta Presión , Dopamina/análisis , Dopamina/metabolismo , Fiebre/inducido químicamente , Hipotálamo/efectos de los fármacos , Hipotálamo/metabolismo , Masculino , Microdiálisis , Ratas , Ratas Wistar , Serotonina/análisis , Serotonina/metabolismo
13.
J Psychopharmacol ; 26(10): 1307-16, 2012 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-22596206

RESUMEN

Δ9-Tetrahydrocannabinol (THC) produces transient psychomimetic effects in healthy volunteers, constituting a pharmacological model for psychosis. The dopaminergic antagonist haloperidol has previously been shown to reduce these effects. This placebo-controlled, cross-over study in 49 healthy, male, mild cannabis users aimed to further explore this model by examining the effect of a single oral dose of olanzapine (with dopaminergic, serotonergic, adrenergic, muscarinergic and histaminergic properties) or two oral doses of diphenhydramine (histamine antagonist) on the effects of intrapulmonarily administered THC. Transient psychomimetic symptoms were seen after THC administration, as measured on the positive and negative syndrome scale (20.6% increase on positive subscale, p<0.001) and the visual analogue scale for psychedelic effects (increase of 10.7 mm on feeling high). Following the combination of THC and olanzapine, the positive subscale increased by only 13.7% and feeling high by only 8.7 mm. This reduction of THC effects on the positive subscale failed to reach statistical significance (p=0.066). However, one-third of the subjects did not show an increase in psychomimetic symptoms after THC alone. Within responders, olanzapine reduced the effects of THC on the positive subscale (p=0.005). Other outcome measures included pharmacokinetics, eye movements, postural stability, pupil/iris ratio, and serum concentrations of cortisol and prolactin.


Asunto(s)
Antipsicóticos/uso terapéutico , Benzodiazepinas/uso terapéutico , Dronabinol/antagonistas & inhibidores , Alucinógenos/antagonistas & inhibidores , Antagonistas de los Receptores Histamínicos H1/uso terapéutico , Trastornos Psicóticos/tratamiento farmacológico , Absorción/efectos de los fármacos , Adolescente , Adulto , Antipsicóticos/sangre , Antipsicóticos/farmacocinética , Benzodiazepinas/sangre , Benzodiazepinas/farmacocinética , Estudios Cruzados , Método Doble Ciego , Dronabinol/sangre , Dronabinol/farmacocinética , Dronabinol/toxicidad , Interacciones Farmacológicas , Consumidores de Drogas , Alucinógenos/sangre , Alucinógenos/farmacocinética , Alucinógenos/toxicidad , Antagonistas de los Receptores Histamínicos H1/sangre , Antagonistas de los Receptores Histamínicos H1/farmacocinética , Humanos , Masculino , Tasa de Depuración Metabólica/efectos de los fármacos , Persona de Mediana Edad , Países Bajos , Síndromes de Neurotoxicidad/sangre , Síndromes de Neurotoxicidad/prevención & control , Olanzapina , Trastornos Psicóticos/sangre , Adulto Joven
14.
Rev. toxicol ; 28(2): 119-134, jul.-dic. 2011. ilus, tab
Artículo en Español | IBECS | ID: ibc-94021

RESUMEN

Los textos cervantinos constituyen una interesante fuente para el estudio de la sociedad española tardorrenacentista. Nosotros hemos abordado las obras de Cervantes desde la óptica de la toxicología, analizando el uso de agentes tóxicos y venenosos, fundamentalmente alucinógenos y narcóticos en el ámbito de la práctica de la brujería y hechicería (ungüentos de brujas, filtros de amor, pócimas venenosas, etc.), así como las menciones a las hipotéticas sustancias dotadas de acción alexifármaca, como la verbena (Verbena officinalis), el cuerno de unicornio, las piedras bezoares o el castóreo. Las obras cervantinas en las que se hace referencia a estos preparados son las novelas El Quijote, La Galatea, Viaje del Parnaso y cuatro Novelas Ejemplares (La española inglesa, El licenciado Vidriera, El celoso extremeño y El coloquio de los perros), así como en las comedias Pedro de Urdemalas, La entretenida y El laberinto del amor. Entre los agentes tóxicos de origen herbal citados expresamente por Cervantes en el contexto analizado se encuentran el beleño (Hyoscyamus niger / albus), el tabaco (Nicotiana tabacum), la adelfa (Nerium oleander), el tártago (Euphorbia lathyris), el ruibarbo (Rheum officinale, Rumex alpinus) y, de forma enmascarada, el opio (Papaver somniferum). En relación con el resto de preparados dotados de actividad tóxica, Cervantes no identifica sus ingredientes, aunque, a tenor de la sintomatología descrita por el autor, podrían ser plantas de la familia de las solanáceas, como el beleño, el solano, la datura, la belladona o la mandrágora. Con respecto a los tóxicos minerales, únicamente hay referencias a los efectos del mercurio o azogue. El Dioscórides comentado por Andrés Laguna pudo ser la fuente técnica utilizada por Cervantes para documentarse en esta materia (AU)


Cervantine texts are an interesting source for the study of Spanish late Renaissance society. We have studied the works of Cervantes from the toxicology viewpoint, analyzing the use of toxic and poisonous substances, essentially hallucinogenic and narcotic agents in the field of witchcraft and sorcery practice (witches ointments, love filters, poisonous potions, etc.), as well as references to hypothetical substances endowed with alexipharmic action, as the vervain (Verbena officinalis), unicorn horn, bezoar stones or castoreum. Cervantine works which refers to these preparations are the novels Don Quixote, The Galatea, Voyage to Parnassus and four Exemplary Novels (The Spanish-English Lady, The Licentiate of Glass, The Jealous Extremaduran and The Colloquy of the Dogs), as well as the comedies Pedro de Urdemalas, The Amusing Woman and The Labyrinth of Love. Toxic agents of herbal origin mentioned explicitly by Cervantes in the analyzed context include the henbane (Hyoscyamus niger / albus), tobacco (Nicotiana tabacum), oleander (Nerium oleander), spurge (Euphorbia lathyris), rhubarb (Rheum officinale, Rumex alpinus), and masked way, opium (Papaver somniferum). In relation to the rest of preparations endowed with toxic activity, Cervantes does not identify its ingredients, though, within the meaning of the symptoms described by the author, they could be plants of the Solanaceae family, as the henbane, nightshade, jimsonweed, belladonna or mandrake. Concerning toxic minerals, only there are references to the effects of mercury (“azogue”). The Dioscorides commented by Andrés Laguna could be the technical font used by Cervantes to document in this matter (AU)


Asunto(s)
Humanos , Masculino , Femenino , Toxicología/historia , Alucinógenos/toxicidad , Opio/toxicidad , Atropa belladonna/toxicidad , Alcaloides de Belladona/toxicidad , Mandragora officinarum/toxicidad , Mandragora/toxicidad , Medicina en las Artes , Solanaceae/toxicidad , Datura stramonium/toxicidad , Datura/toxicidad , Intoxicación por Mercurio/fisiopatología
15.
Pharmacol Biochem Behav ; 98(4): 559-69, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21402097

RESUMEN

Antagonism of prepulse inhibition (PPI) deficits produced by psychotomimetic drugs has been widely used as an effective tool for the study of the mechanisms of antipsychotic action and identifying potential antipsychotic drugs. Many studies have relied on the acute effect of a single administration of antipsychotics, whereas patients with schizophrenia are treated chronically with antipsychotic drugs. The clinical relevance of acute antipsychotic effect in this model is still an open question. In this study, we investigated the time course of repeated antipsychotic treatment on persistent PPI deficit induced by repeated phencyclidine (PCP) treatment. After a baseline test with saline, male Sprague-Dawley rats were repeatedly injected with either vehicle, haloperidol (0.05mg/kg), clozapine (5.0 or 10.0mg/kg), olanzapine (2.0mg/kg), risperidone (1.0mg/kg) or quetiapine (10mg/kg), followed by PCP (1.5mg/kg, sc) and tested for PPI once daily for 6 consecutive days. A single injection of PCP disrupted PPI and this effect was maintained with repeated PCP injections throughout the testing period. Acute clozapine, but not other antipsychotic drugs, attenuated acute PCP-induced PPI disruption at both tested doses. With repeated treatment, clozapine and quetiapine maintained their attenuation, while risperidone enhanced its effect with a significant reduction of PCP-induced disruption toward the end of treatment period. In contrast, repeated haloperidol and olanzapine treatments were ineffective. The PPI effects of these drugs were more conspicuous at a higher prepulse level (e.g. 82dB) and were dissociable from their effects on startle response and general activity. Overall, the repeated PCP-PPI model appears to be a useful model for the study of the time-dependent antipsychotic effect, and may help identify potential treatments that have a quicker onset of action than current antipsychotics.


Asunto(s)
Antipsicóticos/administración & dosificación , Fenciclidina/administración & dosificación , Fenciclidina/toxicidad , Reflejo de Sobresalto/efectos de los fármacos , Estimulación Acústica , Animales , Clozapina/administración & dosificación , Dibenzotiazepinas/administración & dosificación , Interacciones Farmacológicas , Alucinógenos/administración & dosificación , Alucinógenos/toxicidad , Haloperidol/administración & dosificación , Humanos , Masculino , Modelos Animales , Actividad Motora/efectos de los fármacos , Fumarato de Quetiapina , Ratas , Ratas Sprague-Dawley , Reflejo de Sobresalto/fisiología , Risperidona/administración & dosificación
16.
Int J Neuropsychopharmacol ; 14(6): 856-61, 2011 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-21329554

RESUMEN

The aim of this study was to investigate the involvement of serotonin-1A (5-HT(1A)) receptors in the effects of 3,4-methylenedioxymetamphetamine (MDMA) on prepulse inhibition of acoustic startle (PPI) by comparing male and female wild-type (WT) mice and 5-HT(1A) receptor knockout (1AKO) mice. MDMA dose-dependently decreased PPI in male and female mice although female mice were more sensitive at the 100-ms inter-stimulus interval (ISI). In male mice, 10 mg/kg MDMA disrupted PPI in 1AKO but not in WT controls. There was no genotype difference at higher or lower doses of MDMA. In female mice, there was no difference between genotypes at any dose of MDMA. Average startle was reduced by 10 mg/kg and 20 mg/kg MDMA similarly in male and female mice and all genotypes. These results show an involvement of 5-HT(1A) receptors in the effect of MDMA on PPI in male, but not female mice.


Asunto(s)
3,4-Metilenodioxianfetamina/toxicidad , Alucinógenos/toxicidad , Inhibición Neural/efectos de los fármacos , Receptor de Serotonina 5-HT1A/fisiología , 3,4-Metilenodioxianfetamina/administración & dosificación , Estimulación Acústica , Inhibidores de Captación Adrenérgica/administración & dosificación , Inhibidores de Captación Adrenérgica/toxicidad , Animales , Relación Dosis-Respuesta a Droga , Femenino , Alucinógenos/administración & dosificación , Heterocigoto , Drogas Ilícitas/toxicidad , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Receptor de Serotonina 5-HT1A/genética , Reflejo de Sobresalto/efectos de los fármacos , Caracteres Sexuales
17.
J Anal Toxicol ; 33(9): 604-9, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-20040135

RESUMEN

Preparations of the plant Acorus calamus (calamus or sweet flag) (A. calamus) are available via internet trade and marketed as being hallucinogenic. In 2003-2006, the Swedish Poisons Information Centre received inquiries about 30 clinical cases of intentional intoxication with A. calamus products. The present investigation aimed to identify alpha- and beta-asarone, considered active components of A. calamus, and metabolites thereof in urine samples collected in seven of these cases. To further aid the identification of asarone biotransformation products, a calamus oil preparation was incubated with the fungus Cunninghamella elegans, which is used as a microbial model of mammalian drug metabolism. Using gas chromatography-mass spectrometry (GC-MS) analysis in selected ion monitoring mode, alpha-asarone was detected in five urine samples at concentrations ranging between approximately 11 and 1150 microg/L and beta-asarone in four of those at approximately 22-220 microg/L. A previously identified asarone metabolite, trans-2,4,5-trimethoxycinnamic acid (trans-TMC), was detected in the fungus broth by liquid chromatography-tandem mass spectrometry whereas cis-TMC was tentatively identified in the human urine samples. Using GC-MS, a hydroxylated asarone metabolite was identified both in fungus broth and urine samples. However, this study demonstrated no evidence for the presence of 2,4,5-trimethoxyamphetamine, claimed as a hallucinogenic component of A. calamus. The main clinical symptom reported by the patients was prolonged vomiting that sometimes lasted more than 15 h.


Asunto(s)
Acorus , Anisoles/toxicidad , Alucinógenos/toxicidad , Aceites de Plantas/toxicidad , Adolescente , Adulto , Derivados de Alilbenceno , Anfetaminas/orina , Anisoles/orina , Biotransformación , Cromatografía Liquida , Cinamatos/orina , Cunninghamella/metabolismo , Remoción de Radical Alquila , Femenino , Cromatografía de Gases y Espectrometría de Masas , Alucinógenos/orina , Humanos , Hidroxilación , Masculino , Aceites de Plantas/metabolismo , Intoxicación/orina , Espectrometría de Masas en Tándem , Vómitos/inducido químicamente , Vómitos/orina , Adulto Joven
19.
Eur J Pharmacol ; 607(1-3): 178-87, 2009 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-19326570

RESUMEN

The present study examined the adverse effects of delta-9-tetrahydrocannabinol (i.p injection in albino mice) on free radical damage of testicular lipids (lipid peroxidation) at low doses and the role of antioxidant enzymes defense system at high dose and particularly at the withdrawal of the drug after applying higher dose (recovery dose). At lower doses (total doses ranging from 6 mg to 28 mg), there was a significant increase of lipid peroxidation and decrease in testicular lipid content. But the effects were slightly lowered at high dose (total dose 70 mg) and at the withdrawal of the drug (recovery dose). Similarly, marked decrease of antioxidant enzyme systems (superoxide dismutase, catalase, and glutathione peroxidase) and glutathione content were noticed at low doses. But the effects were slightly higher at high dose and at the withdrawal of the drug. Similarly, low-dose treatments caused significant shrinkage of tubular diameter and detrimental changes in seminiferous epithelium of testis resulting in lowered plasma testosterone and pituitary gonadotropins (follicular stimulating and luteinizing hormone levels. But at high dose and particularly at withdrawal of the drug, regression of seminiferous tubules and recovery of various germ cell layers of testes through the revival of testosterone hormone and pituitary gonadotropins were observed.


Asunto(s)
Dronabinol/toxicidad , Alucinógenos/toxicidad , Peroxidación de Lípido/efectos de los fármacos , Testículo/efectos de los fármacos , Animales , Antioxidantes/metabolismo , Catalasa/efectos de los fármacos , Catalasa/metabolismo , Relación Dosis-Respuesta a Droga , Dronabinol/administración & dosificación , Hormona Folículo Estimulante/sangre , Radicales Libres/metabolismo , Glutatión/efectos de los fármacos , Glutatión/metabolismo , Glutatión Peroxidasa/efectos de los fármacos , Glutatión Peroxidasa/metabolismo , Alucinógenos/administración & dosificación , Inyecciones Intraperitoneales , Hormona Luteinizante/sangre , Masculino , Ratones , Estrés Oxidativo/efectos de los fármacos , Superóxido Dismutasa/efectos de los fármacos , Superóxido Dismutasa/metabolismo , Testículo/metabolismo , Testosterona/sangre
20.
Drug Metab Lett ; 2(2): 95-9, 2008 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-19356078

RESUMEN

The purpose of the present review is to examine the effect of the acute administration (20 mg/ Kg, i.p.) of the 3,4 methylenedioxymethamphetamine (MDMA) in different cerebral areas of rats to better understand the mechanism underlying the toxicity induced by cellular oxidative stress. For this purpose the biochemical parameters of the antioxidant non-enzymatic cellular defense system have been studied (the reduced Glutathione (GSH), the Glutathione Disulfide (GSSG), the Ascorbic Acid (AA) and malondialdehyde (MDA) which indicates perioxidative damage) in the hippocampus, striate, frontal cortex both in treated animals and in control groups to realize a qualitative-quantitative evaluation of the possible alterations of the neuronal redox state induced by the administration of Ecstasy. The administration of MDMA induced the following variations of the antioxidant non enzymatic defense system: 1. the levels of the AA in the treated animals compared with the control group were increased in the striate, hippocampus and in the frontal cortex both at 3h and 6h. 2. In the striate, also MDA was significantly increased both after 3 h and 6 h, while in the hippocampus and in the frontal cortex the MDA was significantly increased after 6 h. 3. An increase of GSH was also observed after 3 h and 6 h in the hippocampus and in the striate while no significative variation were observed in the frontal cortex of the treated rats. 4. An increase of GSSG was significative in the hippocampus and striate at 3h, while at 6h it was significative only in the striate. In conclusion the results of our study seem to confirm the role of the oxidative stress in the mechanism of neuronal toxicity induced by Ecstasy and leads us to hypothesize a possible role of the antioxidant substances in the therapeutic treatment of the intoxicants by MDMA.


Asunto(s)
Alucinógenos/toxicidad , N-Metil-3,4-metilenodioxianfetamina/toxicidad , Estrés Oxidativo/efectos de los fármacos , Animales , Lóbulo Frontal/efectos de los fármacos , Lóbulo Frontal/metabolismo , Hipocampo/efectos de los fármacos , Hipocampo/metabolismo , Inyecciones Intraperitoneales , Masculino , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Oxidación-Reducción/efectos de los fármacos , Ratas , Ratas Wistar , Factores de Tiempo , Corteza Visual/efectos de los fármacos , Corteza Visual/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA